{"id":69255,"date":"2026-07-02T15:25:57","date_gmt":"2026-07-02T07:25:57","guid":{"rendered":"https:\/\/flcube.com\/?p=69255"},"modified":"2026-07-02T15:25:58","modified_gmt":"2026-07-02T07:25:58","slug":"junshi-biosciences-licenses-anti-il-17a-antibody-roconkibart-to-fosun-wanbang-for-greater-china-1-34b-deal-secures-commercialization-of-phase-iii-ready-psoriasis-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69255","title":{"rendered":"Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China \u2013 $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Junshi Biosciences<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1877:HKG\">HKG: 1877<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688180:SHA\">SHA: 688180<\/a>) announced a <strong>licensing agreement<\/strong> with <strong>Fosun Wanbang Pharma Group<\/strong>, a subsidiary of <strong>Fosun Pharma<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2196:HKG\">HKG: 2196<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/600196:SHA\">SHA: 600196<\/a>), for the <strong>development, registration, manufacturing, and commercialization<\/strong> of <strong>roconkibart<\/strong> (JS005), an <strong>anti-IL-17A monoclonal antibody<\/strong>, across <strong>Greater China<\/strong> (Mainland China, Hong Kong, Macau, and Taiwan). The deal, valued at up to <strong>RMB 1.34 billion<\/strong> ($185 million), leverages Fosun&#8217;s commercial infrastructure for Junshi&#8217;s Phase III-ready autoimmune therapy.<\/p>\n\n\n\n<h2 id=\"h-transaction-structure-amp-financial-terms\" class=\"wp-block-heading\">Transaction Structure &amp; Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licenser<\/strong><\/td><td>Junshi Biosciences<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Fosun Wanbang Pharma Group (Fosun Pharma subsidiary)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Greater China (Mainland China, Hong Kong, Macau, Taiwan)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Roconkibart (JS005) \u2013 anti-IL-17A monoclonal antibody<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>RMB 215 million (~$30 million)<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Up to RMB 1.125 billion (~$155 million)<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Double-digit tiered percentages of net sales<\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td>Up to RMB 1.34 billion (~$185 million)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-clinical-status\" class=\"wp-block-heading\">Drug Profile &amp; Clinical Status<\/h2>\n\n\n\n<h3 id=\"h-roconkibart-selective-il-17a-inhibitor\" class=\"wp-block-heading\">Roconkibart \u2013 Selective IL-17A Inhibitor<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Binds with high affinity to IL-17A homodimers and IL-17A\/IL-17F heterodimers<\/li>\n\n\n\n<li><strong>Target Specificity:<\/strong> Selectively blocks binding to IL-17RA\/IL-17RC receptors<\/li>\n\n\n\n<li><strong>Downstream Effects:<\/strong> Inhibits inflammatory cytokine release and signaling pathway activation<\/li>\n\n\n\n<li><strong>Therapeutic Application:<\/strong> Autoimmune diseases, particularly moderate-to-severe plaque psoriasis<\/li>\n\n\n\n<li><strong>Development Status:<\/strong> <strong>Phase III registrational study completed<\/strong> in China for adult psoriasis patients<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-clinical-performance\" class=\"wp-block-heading\">Clinical Performance<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Efficacy:<\/strong> Demonstrated excellent efficacy in Phase III psoriasis trial<\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> Favorable safety data supporting regulatory submission<\/li>\n\n\n\n<li><strong>Competitive Position:<\/strong> Positions as potential best-in-class IL-17 inhibitor in Chinese market<\/li>\n\n\n\n<li><strong>Intellectual Property:<\/strong> Independently developed by Junshi with full rights retained pre-licensing<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-opportunity-amp-strategic-rationale\" class=\"wp-block-heading\">Market Opportunity &amp; Strategic Rationale<\/h2>\n\n\n\n<h3 id=\"h-psoriasis-market-dynamics\" class=\"wp-block-heading\">Psoriasis Market Dynamics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Population:<\/strong> Estimated 6-8 million psoriasis patients in China, with 15-20% having moderate-to-severe disease<\/li>\n\n\n\n<li><strong>Current Treatment Gap:<\/strong> Limited access to biologic therapies due to cost and availability constraints<\/li>\n\n\n\n<li><strong>IL-17 Market:<\/strong> Rapidly growing segment with premium pricing potential (\u00a550,000-80,000 annually per patient)<\/li>\n\n\n\n<li><strong>Reimbursement Trajectory:<\/strong> High likelihood of NRDL inclusion following approval<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-partnership-synergies\" class=\"wp-block-heading\">Partnership Synergies<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Junshi Strength:<\/strong> Proven biologics development capability and Phase III clinical success<\/li>\n\n\n\n<li><strong>Fosun Advantage:<\/strong> Extensive commercial infrastructure, hospital access, and distribution network across Greater China<\/li>\n\n\n\n<li><strong>Risk Mitigation:<\/strong> Transfers commercial risk to Fosun while providing Junshi with substantial non-dilutive funding<\/li>\n\n\n\n<li><strong>Strategic Focus:<\/strong> Allows Junshi to concentrate resources on global pipeline and other late-stage assets<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-financial-amp-portfolio-implications\" class=\"wp-block-heading\">Financial &amp; Portfolio Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Immediate Cash Infusion:<\/strong> RMB 215 million upfront strengthens balance sheet for ongoing R&amp;D investments<\/li>\n\n\n\n<li><strong>Revenue Diversification:<\/strong> Royalty stream provides recurring income without operational burden<\/li>\n\n\n\n<li><strong>Valuation Catalyst:<\/strong> Successful commercial launch could significantly enhance Junshi&#8217;s enterprise value<\/li>\n\n\n\n<li><strong>Pipeline Validation:<\/strong> Demonstrates market confidence in Junshi&#8217;s biologics platform and development capabilities<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding partnership outcomes and commercial performance. Actual results may differ due to risks including regulatory approval timelines, market adoption rates, competitive dynamics in the IL-17 space, and reimbursement decisions affecting biologic therapies in Greater China.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Junshi Biosciences (HKG: 1877, SHA: 688180) announced a licensing agreement with Fosun Wanbang Pharma Group,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[65,159,3834,899,893,296,892,900],"class_list":["post-69255","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-auto-immune","tag-fosun-pharmaceutical","tag-fosun-wanbang-pharmaceutical","tag-hkg-1877","tag-hkg-2196","tag-junshi-biosciences","tag-sha-600196","tag-sha-688180"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China \u2013 $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Junshi Biosciences (HKG: 1877, SHA: 688180) announced a licensing agreement with Fosun Wanbang Pharma Group, a subsidiary of Fosun Pharma (HKG: 2196, SHA: 600196), for the development, registration, manufacturing, and commercialization of roconkibart (JS005), an anti-IL-17A monoclonal antibody, across Greater China (Mainland China, Hong Kong, Macau, and Taiwan). The deal, valued at up to RMB 1.34 billion ($185 million), leverages Fosun&#039;s commercial infrastructure for Junshi&#039;s Phase III-ready autoimmune therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69255\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China \u2013 $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy\" \/>\n<meta property=\"og:description\" content=\"Junshi Biosciences (HKG: 1877, SHA: 688180) announced a licensing agreement with Fosun Wanbang Pharma Group, a subsidiary of Fosun Pharma (HKG: 2196, SHA: 600196), for the development, registration, manufacturing, and commercialization of roconkibart (JS005), an anti-IL-17A monoclonal antibody, across Greater China (Mainland China, Hong Kong, Macau, and Taiwan). The deal, valued at up to RMB 1.34 billion ($185 million), leverages Fosun&#039;s commercial infrastructure for Junshi&#039;s Phase III-ready autoimmune therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69255\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-02T07:25:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-02T07:25:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69255#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69255\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China \u2013 $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy\",\"datePublished\":\"2026-07-02T07:25:57+00:00\",\"dateModified\":\"2026-07-02T07:25:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69255\"},\"wordCount\":469,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Fosun Pharmaceutical\",\"Fosun Wanbang Pharmaceutical\",\"HKG: 1877\",\"HKG: 2196\",\"Junshi Biosciences\",\"SHA: 600196\",\"SHA: 688180\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69255#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69255\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69255\",\"name\":\"Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China \u2013 $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-02T07:25:57+00:00\",\"dateModified\":\"2026-07-02T07:25:58+00:00\",\"description\":\"Junshi Biosciences (HKG: 1877, SHA: 688180) announced a licensing agreement with Fosun Wanbang Pharma Group, a subsidiary of Fosun Pharma (HKG: 2196, SHA: 600196), for the development, registration, manufacturing, and commercialization of roconkibart (JS005), an anti-IL-17A monoclonal antibody, across Greater China (Mainland China, Hong Kong, Macau, and Taiwan). The deal, valued at up to RMB 1.34 billion ($185 million), leverages Fosun's commercial infrastructure for Junshi's Phase III-ready autoimmune therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69255#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69255\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69255#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China \u2013 $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China \u2013 $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"Junshi Biosciences (HKG: 1877, SHA: 688180) announced a licensing agreement with Fosun Wanbang Pharma Group, a subsidiary of Fosun Pharma (HKG: 2196, SHA: 600196), for the development, registration, manufacturing, and commercialization of roconkibart (JS005), an anti-IL-17A monoclonal antibody, across Greater China (Mainland China, Hong Kong, Macau, and Taiwan). The deal, valued at up to RMB 1.34 billion ($185 million), leverages Fosun's commercial infrastructure for Junshi's Phase III-ready autoimmune therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69255","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China \u2013 $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy","og_description":"Junshi Biosciences (HKG: 1877, SHA: 688180) announced a licensing agreement with Fosun Wanbang Pharma Group, a subsidiary of Fosun Pharma (HKG: 2196, SHA: 600196), for the development, registration, manufacturing, and commercialization of roconkibart (JS005), an anti-IL-17A monoclonal antibody, across Greater China (Mainland China, Hong Kong, Macau, and Taiwan). The deal, valued at up to RMB 1.34 billion ($185 million), leverages Fosun's commercial infrastructure for Junshi's Phase III-ready autoimmune therapy.","og_url":"https:\/\/flcube.com\/?p=69255","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-02T07:25:57+00:00","article_modified_time":"2026-07-02T07:25:58+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69255#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69255"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China \u2013 $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy","datePublished":"2026-07-02T07:25:57+00:00","dateModified":"2026-07-02T07:25:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69255"},"wordCount":469,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Fosun Pharmaceutical","Fosun Wanbang Pharmaceutical","HKG: 1877","HKG: 2196","Junshi Biosciences","SHA: 600196","SHA: 688180"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69255#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69255","url":"https:\/\/flcube.com\/?p=69255","name":"Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China \u2013 $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-02T07:25:57+00:00","dateModified":"2026-07-02T07:25:58+00:00","description":"Junshi Biosciences (HKG: 1877, SHA: 688180) announced a licensing agreement with Fosun Wanbang Pharma Group, a subsidiary of Fosun Pharma (HKG: 2196, SHA: 600196), for the development, registration, manufacturing, and commercialization of roconkibart (JS005), an anti-IL-17A monoclonal antibody, across Greater China (Mainland China, Hong Kong, Macau, and Taiwan). The deal, valued at up to RMB 1.34 billion ($185 million), leverages Fosun's commercial infrastructure for Junshi's Phase III-ready autoimmune therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69255#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69255"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69255#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China \u2013 $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69255","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69255"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69255\/revisions"}],"predecessor-version":[{"id":69257,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69255\/revisions\/69257"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69255"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69255"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69255"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}